QTRT1: A Potential Drug Target and Biomarker for tRNA-Guanine Transglycosylase

Target Name: QTRT1

NCBI ID: G81890

QTRT1

QTRT1: A Potential Drug Target and Biomarker for tRNA-Guanine Transglycosylase

Introduction

QTRT1 (Qut disintegrin) is a protein that is expressed in most tissues of the body. It is a key regulator of microRNA (miRNA) translation, which plays a crucial role in post-transcriptional gene regulation. tRNA-Guanine Transglycosylase ( tRNA-GT) is a key enzyme in the process of miRNA translation, and it is dependent on QTRT1 for its activity. Therefore, changes in QTRT1 expression levels have been reported to be associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

The Importance of QTRT1 in miRNA Translation

QTRT1 is a critical regulator of miRNA translation, which is a process that involves the translation of pre-mRNA into functional miRNA molecules. The translation of miRNA molecules is a highly regulated process, and multiple factors are involved in this process, including the interaction between the miRNA and the cell's translation machinery.

QTRT1 is involved in the regulation of miRNA translation by promoting the loading of the miRNA onto the ribosome, the initiation of translation, and the termination of translation. It does this by interacting with the sarcosylated nucleolus, which is a subunit of the ribosome that is responsible for loading the miRNA onto the ribosome.

In addition to its role in miRNA translation, QTRT1 is also involved in the regulation of miRNA stability and localization. It has been shown that QTRT1 can interact with the miRNA secondary structure, which is composed of a variety of base pairs that can be targeted by different enzymes for degradation or translation. This interaction between QTRT1 and the miRNA secondary structure allows QTRT1 to regulate the stability and localization of miRNA molecules.

Potential Therapeutic Applications of QTRT1

The potential therapeutic applications of QTRT1 are vast, as its involvement in miRNA translation and stability make it a promising target for the development of new drugs. Here are some potential therapeutic applications of QTRT1:

1. Cancer Therapies:

QTRT1 has been shown to be highly expressed in various types of cancer, including breast cancer, lung cancer, and colon cancer. Therefore, targeting QTRT1 with drugs that can inhibit its activity could be an effective cancer therapeutic approach. For example, inhibitors of QTRT1 have been shown to be effective in preclinical studies in treating various types of cancer.

2. Neurodegenerative Diseases:

QTRT1 is also involved in the regulation of miRNA translation in neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Therefore, targeting QTRT1 with drugs that can inhibit its activity could be an effective approach to treating neurodegenerative diseases.

3. Autoimmune Diseases:

QTRT1 is also involved in the regulation of miRNA translation in autoimmune diseases, including rheumatoid arthritis and multiple sclerosis. Therefore, inhibitors of QTRT1 have been shown to be effective in preclinical studies in treating autoimmune diseases.

4. Antiviral Therapies:

QTRT1 has also been shown to be involved in the regulation of miRNA translation in antiviral therapies. For example, inhibitors of QTRT1 have been shown to be effective in preclinical studies in treating influenza and herpes simplex virus (HSV) infections.

Conclusion

In conclusion, QTRT1 is a protein that plays a critical role in the regulation of miRNA translation, and its activity is involved in various diseases, including cancer, neurodegenerative diseases, autoimmune diseases, and antiviral therapies. Therefore, targeting QTRT1 with drugs that can inhibit its activity could be an effective approach to treating these diseases. Further research is needed to

Protein Name: Queuine TRNA-ribosyltransferase Catalytic Subunit 1

Functions: Catalytic subunit of the queuine tRNA-ribosyltransferase (TGT) that catalyzes the base-exchange of a guanine (G) residue with queuine (Q) at position 34 (anticodon wobble position) in tRNAs with GU(N) anticodons (tRNA-Asp, -Asn, -His and -Tyr), resulting in the hypermodified nucleoside queuosine (7-(((4,5-cis-dihydroxy-2-cyclopenten-1-yl)amino)methyl)-7-deazaguanosine) (PubMed:11255023, PubMed:20354154). Catalysis occurs through a double-displacement mechanism. The nucleophile active site attacks the C1' of nucleotide 34 to detach the guanine base from the RNA, forming a covalent enzyme-RNA intermediate. The proton acceptor active site deprotonates the incoming queuine, allowing a nucleophilic attack on the C1' of the ribose to form the product (By similarity)

The "QTRT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about QTRT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets